Skip to main content
Novacyt logo

Novacyt — Investor Relations & Filings

Ticker · ALNOV ISIN · FR0010397232 LEI · 213800BWAC2BF295EG28 PA Manufacturing
Open in API
Filings indexed 1,101 across all filing types
Latest filing 2022-08-01 Regulatory Filings
Country FR France
Listing PA ALNOV

About Novacyt

https://novacyt.com/

Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services. The company's core activities include the design, development, manufacturing, and commercialization of in vitro and molecular diagnostic tests, with a specialization in real-time PCR (qPCR) kits and reagents. Novacyt's solutions are applied across various markets, including clinical diagnostics for human health, with a focus on infectious diseases and oncology, as well as animal health and food safety. The company also offers custom development services, contract manufacturing, and pharmaceutical research services such as whole genome sequencing.

Recent filings

Filing Released Lang Actions
Liquidity Agreement and Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is an official announcement disseminated via RNS (RNS Number: 4855U) from Novacyt S.A. The content primarily details two items: 1) A monthly update on the company's Liquidity Agreement (share purchases/sales by the liquidity provider) for July 2022, and 2) The announcement of the Total Voting Rights as of July 31, 2022. Announcements regarding share transactions, treasury shares, and total voting rights are common components of regulatory disclosures that do not fit into specific financial reporting categories like 10-K or ER. Since it is a formal, periodic regulatory update that doesn't match any other specific category (like DIRS for director dealing, or POS for company share repurchase program details, although it relates to treasury shares), the most appropriate general category for miscellaneous regulatory announcements is RNS (Regulatory Filings). The document length is moderate, but its nature is purely informational/regulatory update, not a full report.
2022-08-01 English
Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote
Transaction in Own Shares Classification · 99% confidence The document is titled "Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote" (Monthly information on the liquidity contract and on the total number of voting rights). It details the monthly activity (purchases and sales of shares) under a liquidity contract (share buyback/stabilization program) for the period July 1 to July 31, 2022, and reports the total number of voting rights. This content specifically relates to the company managing its own shares, which aligns directly with the definition of 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), an interim report (IR), or a major shareholding notification (MRQ) concerning third-party investors, but rather a report on the company's own share transactions.
2022-08-01 French
Launch of research-use-only adenovirus F41 assay
Regulatory Filings Classification · 100% confidence The document is identified by the header 'RNS Number' and contains a date (28 July 2022) and company information, typical of a regulatory news service announcement. The content describes the launch of a new research-use-only diagnostic assay (adenovirus F41 assay) by Novacyt S.A. This is a specific operational/product announcement, not a comprehensive financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since it is a specific announcement distributed via the RNS system, and it is not one of the highly specific categories like DIRS, DIV, or ER, it falls best under the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous regulatory news that doesn't fit elsewhere, especially since the footer explicitly mentions 'Reach is a non-regulatory news service' distributed via RNS.
2022-07-28 English
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated July 28, 2022, announcing the 'Launch of research-use-only adenovirus F41 assay' by Novacyt. It details a new product launch in response to public health concerns (acute hepatitis in children) and positions this as part of the company's strategy. This type of announcement, focusing on a specific operational or product development event rather than mandated periodic financial reporting (like 10-K or IR) or management changes (MANG), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report, earnings release (ER), or a specific transaction notice (CAP, POS, TAR), the most appropriate general category for a significant, non-periodic operational announcement is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory news.
2022-07-28 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release dated July 28, 2022, announcing the launch of a new research-use-only (RUO) PCR test for Adenovirus F41. It details the product, its context (recent acute hepatitis cases in children), and includes quotes from the CEO. This type of announcement, focusing on a specific product launch or operational update that is not a mandatory periodic financial filing (like 10-K or IR) or a formal earnings release (ER), fits best under the general category for regulatory announcements or news releases that don't fit other specific categories. Since it is a specific news announcement about a product launch and not a formal financial report, it is classified as a Regulatory Filing (RNS) as the most appropriate general news/announcement category, although it shares characteristics with an Investor Presentation (IP) in terms of strategic communication, the format is clearly a press release announcing a development.
2022-07-28 French
Results of AGM
AGM Information Classification · 99% confidence The document explicitly mentions 'Results of AGM' and states that 'all resolutions proposed at the ordinary general meeting part of the Company's Annual General Meeting (AGM), held today, were duly passed.' This directly relates to the outcomes and information presented at the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document is short and serves as an announcement of the results, but the core subject matter is the AGM itself, making AGM-R more specific than RPA or RNS.
2022-07-20 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.